GET DAILY SIGNALSWhy Is Guardant Health (GH) Stock Down -6.66% Today?
Key Takeaways
- GH shares fell 6.66% in Thursday's session, extending an after-hours slide that followed third-quarter results.
- The primary catalyst was a mixed earnings report: revenue and adjusted EPS beat estimates, but a raised free-cash-flow-burn outlook spooked investors.
- Secondary pressure came from sector-wide weakness in blood-testing and liquid-biopsy names after a rival's disappointing screening report.
- Broader concerns centered on oncology pricing lagging volume growth and rising operating expenses tied to the Shield commercial buildout.
- Traders are now watching reimbursement updates, upcoming catalyst milestones, and whether the stock can reclaim key technical levels.
- For deeper data, explore Guardant Health's Price Targets, Earnings, and Forecast pages.
- To see which strategies are performing best right now, explore the Trending AI Robots.
Opening Summary
Guardant Health, Inc. (GH), a precision-oncology company specializing in blood-based and tissue tests for cancer screening, recurrence monitoring, and treatment selection, traded sharply lower on Thursday. The stock fell 6.66%, closing near $143.21 versus a prior session close of $153.43, a decline of roughly $10.22 per share. The selloff extended the stock's negative reaction to third-quarter 2026 results reported late Wednesday, which topped headline estimates but disappointed investors on cash-burn guidance and pricing trends.
Earnings Beat Overshadowed by Cash-Burn Guidance
GH reported third-quarter revenue of approximately $361 million, up 36% year over year and ahead of consensus estimates near $351 million. Adjusted net loss came in at $0.29 per share, narrower than the year-ago loss of $0.39 and better than most Street forecasts. Management also raised its full-year revenue outlook to a range of $1.36 billion to $1.37 billion, the third consecutive upward revision.
Despite the top-line strength, investors focused on guidance for free cash flow burn, which was raised to $205 million to $220 million from a prior $195 million to $205 million. The increase reflected a temporary CMS claims-processing delay tied to Guardant360 Liquid CDx, which shifted an estimated $10 million to $15 million in payments into 2027. For a company still burning cash, the upward revision in cash outflow outweighed the revenue beat and triggered the post-earnings decline.
Oncology Volume Growth Outpacing Revenue
A second bearish signal was the divergence between volume and pricing in the core Oncology franchise. Oncology test volume surged 58% year over year to 117,000 tests, yet Oncology revenue rose only 25% to roughly $231 million. Revenue growing at less than half the pace of volume points to declining revenue per test, a dynamic that gave bears ammunition about the profitability of the legacy business funding the Shield expansion.
Rising costs reinforced the concern. Non-GAAP operating expenses climbed 26% to about $287 million as the company invested in commercial infrastructure and marketing, and management again raised its full-year operating-expense guidance.
Sector-Wide Sympathy Selling
The decline was amplified by broader weakness across the liquid-biopsy and blood-testing group. A lackluster screening report from peer Grail (GRAL) weighed on sentiment ahead of Guardant's own release, and rival Natera (NTRA) also tumbled in extended trading. The synchronized selloff suggested investors were reassessing valuations and screening demand across the entire sector rather than reacting to Guardant-specific news alone.
Market Context and Trading Activity
Trading volume in GH was elevated relative to recent sessions as participants repriced the stock following the report. The move diverged from the broader market, indicating company- and sector-specific pressure rather than a macro-driven decline. On a technical basis, the stock slipped below its 50-day moving average, a closely watched level that had provided support during the prior advance, adding to the near-term selling momentum.
What Comes Next for GH
Looking ahead, investors will monitor whether Shield screening volumes sustain their rapid growth—Shield revenue jumped 180% to about $68 million on 83,000 tests—and whether the cost per test, which fell to $330 from $410 in the prior quarter, keeps improving toward management's longer-term target. Key catalysts include the continued rollout of the FDA-approved Guardant360 CDx companion diagnostic for ESR1-mutated breast cancer, a pending ADLT reimbursement application, and the planned year-end clinical launch of Reveal Ultra. Reimbursement decisions and the pace of Oncology pricing recovery remain the primary risks and uncertainties for GH shares in the quarters ahead.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the bots demonstrating standout results in the present environment are featured in this section. Explore the Trending AI Robots to discover strategies that align with your trading approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
GH in upward trend: 10-day moving average broke above 50-day moving average on October 29, 2026
The 10-day moving average for GH crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 244 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 188 of 210 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 23 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 65 cases where GH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In 71 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
GH moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
GH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-92.386) is normal, around the industry mean (66.084). P/E Ratio (-43.712) is within average values for comparable stocks, (2.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties
Advertisement